Johns Hopkins ABX Guide
Raltegravir
Raltegravir is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Treatment of HIV-1 infection in combination with other ARV agents in ART-experienced patients with evidence of HIV replication despite ongoing ART.
- Treatment of HIV-1 infection in combination with other ARV agents in ART-naive patients.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- HIV-1 nonoccupational postexposure prophylaxis (nPEP): 400 mg tablet twice daily for 28 days in combination with other antiretrovirals. Therapy should be initiated within 72 hours.
- HIV-1 occupational postexposure prophylaxis (oPEP): 400 mg twice daily for 4 weeks with concomitant emtricitabine/tenofovir. Therapy should be initiated as soon as possible after occupational exposure.
- Substitution for other ARV agents due to drug toxicity or intolerance in pts on a suppressive regimen
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- Treatment of HIV-1 infection in combination with other ARV agents in ART-experienced patients with evidence of HIV replication despite ongoing ART.
- Treatment of HIV-1 infection in combination with other ARV agents in ART-naive patients.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- HIV-1 nonoccupational postexposure prophylaxis (nPEP): 400 mg tablet twice daily for 28 days in combination with other antiretrovirals. Therapy should be initiated within 72 hours.
- HIV-1 occupational postexposure prophylaxis (oPEP): 400 mg twice daily for 4 weeks with concomitant emtricitabine/tenofovir. Therapy should be initiated as soon as possible after occupational exposure.
- Substitution for other ARV agents due to drug toxicity or intolerance in pts on a suppressive regimen
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: February 12, 2022
Citation
Kilcrease, Christin. "Raltegravir." Johns Hopkins ABX Guide, The Johns Hopkins University, 2022. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540471/all/Raltegravir.
Kilcrease C. Raltegravir. Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540471/all/Raltegravir. Accessed August 9, 2022.
Kilcrease, C. (2022). Raltegravir. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540471/all/Raltegravir
Kilcrease C. Raltegravir [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. [cited 2022 August 09]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540471/all/Raltegravir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Raltegravir
ID - 540471
A1 - Kilcrease,Christin,Pharm.D.
Y1 - 2022/02/12/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540471/all/Raltegravir
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
